GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Oral GLP-1

Company
University Hospital, Basel, Switzerland
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Oral GLP-1 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07244003

    Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

    Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 430 participants Est. completion 2028-06-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00468884

    Oral Administration of Peptides; Absorption From Gastrointestinal Tract

    Not yet reported University Hospital, Basel, Switzerland 12 participants Est. completion 2007-02 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00822003

    Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile in Healthy Male Subjects

    Not yet reported, Not yet reported University Hospital, Basel, Switzerland 16 participants Est. completion 2008-09 1 site
    Other conditions: Glucose Homeostasis
    View official trial listing →
  • Completed NCT NCT00822705

    Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36

    Not yet reported, Not yet reported University Hospital, Basel, Switzerland 16 participants Est. completion 2009-01 1 site
    Other conditions: Anti Obesity Agent
    View official trial listing →
  • Terminated NCT NCT05297045

    A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

    Not yet reported Regor Pharmaceuticals Inc. 17 participants Est. completion 2023-05-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT05671653

    A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

    Not yet reported Pfizer 32 participants Est. completion 2023-11-03 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06584916

    A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

    Not yet reported Eli Lilly and Company 376 participants Est. completion 2025-11-21 29 sites
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07668336

    A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 170 participants Est. completion 2030-03 71 sites
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

The Weekly Dose & livestreams

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.